“Multiple sclerosis (MS) is a chronic inflammatory disease of the CNS.
Therapies that affect the endocannabinoid (EC) system may have immunomodulatory, symptomatic and neuroprotective effects.
The aim of this study was to determine how levels of EC and related compounds are altered in MS.
The EC system is altered in MS. It may be dynamically modulated depending on the subtype of the disease, but further studies with larger subgroups are needed to confirm this.”